Breast Cancer Female
Conditions
Keywords
≥65 Years Old, early breast cancer
Brief summary
The elderly patients over 65 years old with breast cancer have concomitant diseases, poor tolerance to conventional treatment, and the specific prognosis of breast cancer is relatively good. Previous studies on breast cancer have almost excluded elderly breast cancer patients, and conventional treatment schemes cannot meet the clinical diagnosis and treatment needs of elderly breast cancer patients. The establishment of a prognosis model for elderly breast cancer patients can provide personalized treatment programs. This is important for prolonging the survival time of patients and improving the quality of life. This project plans to observe the relationship between prognosis and pathological staging, molecular typing, and concomitant diseases of elderly breast cancer patients in combination with immune genes, and establish a prognosis model of elderly breast cancer and verify it. This project is expected to establish a new prognostic model for elderly breast cancer patients, accurately judge the prognosis of patients, and provide a new basis for hierarchical and personalized treatment of elderly breast cancer.
Interventions
PROCEDUREoperation
operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
DRUGBisphosphonate
Bisphosphonate
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
65 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* female patients with breast cancer * ≥65 Years Old * patients with breast cancer received operation in Peking Union Medical College Hospital * treatment regimen was made in Peking Union Medical College Hospital
Exclusion criteria
* patients with metastasis * patietns with recurrence * patients without pathological information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 5-y DFS | 5 year | 5-years of disease free survival |
| 5-y BCSS | 5 year | 5-year of breast cancer-specific survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 5-y OS | 5 year | 5-year overall survival |
| 10-y DFS | 10 year | 10-years of disease free survival |
| 10-y BCSS | 10 year | 10-year of breast cancer-specific survival |
| 10-y OS | 10 year | 10-year overall survival |
Countries
China
Contacts
Primary ContactYing Zhong
Backup ContactXuefei Wang
Outcome results
None listed